Latest Advances in Kidney Cancer Diagnostics Pushing Uptake by 2x through 2031: Fact.MR
29 Oct 2021
AntibodySmall molecular drugAcquisitionCollaborate
Immunohistochemistry Test Emerges as Top Choice for Renal Cell Carcinoma Diagnosis in Kidney Cancer Diagnostics Market: Fact.MR
The kidney cancer diagnostics market survey offers compelling insights into key factors impacting growth strategies across key segments including test, indication, and end-user. It also highlights strategies adopted by vendors to increase sales in kidney cancer diagnostics market.
Fact.MR – A Market Research and Competitive Intelligence Provider: The global kidney cancer diagnostics market is expected to reach a valuation of US$ 1.2 Bn, registering a CAGR of 7% during the forecast period (2021-2031). Demand for immunohistochemistry tests are set to rise at a CAGR of 6% during the forecast period.
As per the report published by Fact.MR, top 5 companies in the global kidney cancer diagnostics market occupy 50% of the market. The cases of kidney cancer are rising in recent years, especially among geriatric population. Numerous private organizations and government agencies across the globe are actively working towards spreading awareness about kidney cancer.
With rapidly rising cases of kidney cancer, consumers are expected to witness affordable and accessible diagnosis associated with treatment of kidney cancer.
Increasing technological developments in devices, increasing demand for blood chemistry test for kidney cancer diagnostics, and investment in healthcare spending is expected to drive the demand for kidney cancer diagnostics market.
Surging demand for microscopic techniques to identify antigens and suppressed tumor genes to diagnose kidney cancer at an early stage have improved the adoption of immunohistochemistry test.
Request a report sample to gain comprehensive insights at
On the back of this, sales of immunohistochemistry tests for kidney cancer diagnostics are expected to increase by 2.2x over the forecast period, estimates Fact.MR.
Also, 3D printing, robotic surgery, telemedicine, and artificial intelligence are some of the major technological advancements. With focus on research and development activities, governments across the globe are taking numerous steps to strengthen kidney cancer diagnostic systems.
“Healthcare service providers and manufacturers in the kidney cancer diagnostic systems are providing personalized patient care for renal cell carcinoma kidney cancer treatment and complete medical services and device products. Investments in affordable operational costs and improving product prototyping will generate lucrative growth opportunities for players,” says the Fact.MR analyst.
Key Takeaways
The U.S. kidney cancer diagnostics market is expected to rise by 1.4x through 2031 on the back of increasing cases of renal cell carcinoma kidney cancer and other chronic diseases.
Sales of kidney cancer diagnostics are rising in China as patients are seeking advanced kidney cancer diagnostics tests owing to the surging kidney cancer cases and lower drug production costs.
Demand for immunohistochemistry tests are expected to grow two-fold as it is preferred more for diagnose of kidney cancer and other diseases that involve antigen-antibody reactions.
Hospitals associated labs are expected to remain primary choice in end-user by patients as hospitals are expanding their capacity and are implementing a variety of strategies to deliver necessary services.
Growth Drivers
With expanding patient pool in kidney cancer, the demand for early kidney cancer diagnostics test is expected to bolster over the assessment period.
Favorable initiatives and investments undertaken by government bodies and private organizations to grow awareness regarding cancer is encouraging sales of kidney cancer diagnostics across the globe.
To gain in-depth insights on Kidney Cancer Diagnostics Market, request methodology at
Competitive Landscape
Players in the global kidney cancer diagnostics are partnering with various regional health ministries and medical administrators to assess the therapeutic diagnosis’s effect on kidney cancer patients.
Medical leaders and organizations in the global pharmaceuticals industry are aiding the development of advanced kidney stone diagnosis market. They are also investing in research and development activities to develop advanced technologies and penetrate deeper in regional market.
For instance,
In February 2021, Renalytix AI PLC, an artificial intelligence-enabled in vitro diagnostics company, announced its partnership with University of Utah, one of the top research institutions in the U.S. to improve kidney health and reduce the risk of kidney failure for large scale populations in the earliest stages of kidney disease.
Some of the players operating in the global kidney cancer diagnostics market as profiled by Fact.MR are:
Myriad Genetics Inc.
NeoGenomics Laboratories
NanoString Technologies Inc.
Sysmex Corporation
Rosetta Genomics
Illumina Inc.
Quest Diagnostics Incorporated
Roche Holding AG
Thermo Fisher Scientific Inc.
Abbott Laboratories
More Insights on the Kidney Cancer Diagnostics Market
Fact.MR provides an unbiased analysis of the kidney cancer diagnostics market presenting historical demand data (2016-2020) and forecast statistics for the period from 2021 to 2031. The study divulges into compelling insights on the kidney cancer market with detailed segmentation on the basis of:
Test
Immunohistochemistry Test for Kidney Cancer Diagnostics
Complete Blood Count Test for Kidney Cancer Diagnostics
Urine Test for Kidney Cancer Diagnostics
Blood Chemistry Test for Kidney Cancer Diagnostics
Indication
Renal Cell Carcinoma Kidney Cancer
Transitional Cell Carcinoma Kidney Cancer
Kidney Sarcoma Kidney Cancer
Wilms Tumor Kidney Cancer
Kidney Lymphoma Kidney Cancer
End User
Hospital-associated Labs for Kidney CancerKidney Cancer Diagnostics
Independent Diagnostic Laboratories for Kidney CancerCancer Diagnostics
Cancer Research Institutes for Kidney Cancer Diagnostics
Others
Metastatic Kidney Cancer Therapy
Nephrectomy Therapy for Kidney Cancer
Cytokine-based Treatment for Kidney Cancer
Diagnostic Laboratories for Kidney Cancer
Diagnostics Test for Kidney Cancer
By Region:
North America
Latin America
Europe
East Asia
South Asia
Oceania
Middle East & Africa
Key questions Covered in the Kidney Cancer Diagnostics Market Report
The report offers detailed insights into kidney cancer diagnostics demand outlook for 2021-2031
The market study also highlights projected sales growth for kidney cancer diagnostics market between 2021 and 2031
Kidney cancer diagnostics market survey identifies key growth drivers, restraints, and other forces impacting prevailing trends, evaluation of current market size, and technological advancements within the industry
Kidney cancer diagnostics market share analysis of the key companies within the industry and coverage of strategies such as mergers & acquisitions, joint ventures, collaborations or partnerships, and others
Explore Fact.MR’s Coverage on the Healthcare Domain –
Cancer Biomarkers Market- The rising incidence of cancer has permitted substantial cancer research in terms of diagnosis and treatment. Clinical trials are increasingly being funded by governments to aid corporations in developing effective cancer diagnosis and treatments. Governments' aggressive funding initiatives for cancer diagnostics are expanding the market for cancer biomarkers. Demand for cancer biomarkers will be bolstered by factors such as the availability of low-cost, non-invasive prognosis.
Oncology Small Molecule Drugs Market- The widespread occurrence of cancer and the resulting need for oral, easily absorbable, and effective therapies has fueled the development of small molecule drugs. The key demand driving determinant is expected to be rapid technology improvement in the healthcare sector. Oncology small molecule drugs sales are being boosted by increased awareness of the availability of new and easy-to-absorb medicines for cancer treatment. Furthermore, oncology small molecule medications are in great demand due to the rising prevalence of cancer and the growing demand for effective therapies.
Cancer Genomic Testing Market- Cancer genomic testing is a relatively recent branch of genetics that is used to diagnose many types of cancer. Over the projection period, the rising prevalence of breast cancer and lung cancer is the key driver driving the growth of the cancer genomic testing market. Furthermore, the rise in cancer awareness campaigns by non-governmental organizations (NGOs) will boost the revenue growth of the cancer genomic testing market. Furthermore, the major manufacturer's focus on developing novel methods for cancer genomic testing is expected to boost the market's revenue growth over the forecast period.
About Fact.MR
Fact.MR is a market research and consulting agency with deep expertise in emerging market intelligence. Spanning a wide range – from automotive & industry 4.0 to healthcare, technology to even the most niche categories. 80% of Fortune 1000's trust us in critical decision making.
MarketNgage is powered by Fact.MR – our Unified Intelligence Engine, a revolutionary Market Research Subscription platform with a flexible pricing to suit your needs.
You can access all our healthcare research reports by signing up with MarketNgage’s Market Research Subscription with FREE credits. MarketNgage is powered by Fact.MR – A Fully integrated research solution for seamless single-window access Widest coverage on emerging markets, nascent products, and disruptive technologies.
Contact:
Mahendra Singh
US Sales Office
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
E: sales@factmr.com
Source: Fact.MR
Organizations
Indications
Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.